Patent ID: 8618115

Claim:
A compound or a pharmaceutically acceptable salt or a stereoisomer or a prodrug thereof according to formula I: wherein, R 1 is independently selected from the group consisting of hydrogen, halogen, lower alkyl, lower cycloalkyl, aryl, CF 3 , CN, NR 7 R 7 , OR 6 and SR 6 ; R 2 is selected from the group consisting of hydrogen and lower alkyl; R 3 is independently selected from the group consisting of hydrogen and lower alkyl; R 4 is G-D 2 -Z n ; R 5 is selected from the group consisting of hydrogen, hydroxyl, halogen, lower alkyl, lower cycloalkyl, CF 3 , SR 6 , lower alkoxy, lower cycloalkoxy, CN, CONR 7 R 7 , SOR 6 , SO 2 R 6 , NR 7 COR 7 , NR 7 CO 2 R 7 , CO 2 R 6 , heteroaryl, NR 7 SO 2 R 6 and COR 6 ; m is an integer from 0 to 1; n is an integer from 1 to 3; when G is selected from the group consisting of O and S, D 2 is selected from the group consisting of lower alkyl, lower cycloalkyl and a 4 to 6-membered non-basic heterocycle; when G is CR 7 R 7 , D 2 is selected from the group consisting of a direct bond, lower alkyl, lower cycloalkyl and a 4 to 6-membered non-basic heterocycle; Z is selected from the group consisting of hydroxyl, lower cycloalkyl, lower cycloalkoxy, OCOR 6 , CN, OSO 2 R 6 , SR 6 , SOR 6 , SO 2 R 6 , CO 2 R 7 , OPO(OR 6 ) 2 , and COR 6 ; R 6 is independently selected from the group consisting of lower alkyl, lower cycloalkyl, heterocycle and heteroaryl; and R 7 is independently selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl and heterocycle, wherein two R 7 and the atom to which they are attached may optionally form a ring of 4 to 7 atoms; wherein said prodrug is selected from the group consisting of an alanine ester, a valine ester, a lysine ester, an aspartate ester, a glutamate ester, a glycine ester, a phenylalanine ester, a proline ester, a leucine ester, a half oxalate ester acid, a half malonate ester acid, a half succinate ester, a phosphonate or phosphinate, a glucoside and a half glutarate ester.